X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

December 09, 2019

Evaluation of Container Systems with Residual Seal Force (RSF)

Parenteral drug products must be stored in a container system that provides good container closure integrity (CCI) over shelf life for the purpose of preventing environmental contamination. This system typically comprises a glass vial, elastomer stopper, and an aluminum seal. USP Chapter &lt;1207&gt; <em>Packaging Integrity Evaluation &ndash; Sterile Products</em> discusses in detail methods to measure CCI to determine if the system can meet the maximum allowable leak limit (MALL) for its specific drug product (i.e., the smallest gap, or leak rate, that places quality at risk). Critical to achieving good CCI is proper capping of the vial with the stopper and seal, making sure that the compression level of the stopper is appropriate.
West Pharma

Mary Tan

Specialist, Scientific Affairs, Singapore, Jurong

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Scientist performing tests in a lab

    January 12, 2018

    Alert: USP <381> Revision Bulletin

    Jen Riter

    Jennifer Riter

    Sr. Director, Labs Services, SA & TS

    CCI Testing

    December 07, 2017

    CCI Testing – What You Need to Know

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    Fran DeGrazio

    July 18, 2017

    USP Particle Workshop – Addressing Issues and Improving Clarity

    Fran DeGrazio

    Fran DeGrazio

    Vice President, Scientific Affairs & Technical Services

    Load more